148 related articles for article (PubMed ID: 36152348)
1. Irisin inhibits PCSK9 expression through activating AMPK-SREBP2 pathway.
Xu R; Liu Q; Ma X; Hou J
Biochem Biophys Res Commun; 2022 Nov; 630():77-83. PubMed ID: 36152348
[TBL] [Abstract][Full Text] [Related]
2. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
3. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
[TBL] [Abstract][Full Text] [Related]
4. Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells.
Wu YR; Li L; Sun XC; Wang J; Ma CY; Zhang Y; Qu HL; Xu RX; Li JJ
Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):322-332. PubMed ID: 33500108
[TBL] [Abstract][Full Text] [Related]
5. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
[TBL] [Abstract][Full Text] [Related]
6. Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.
Tang H; Yu R; Liu S; Huwatibieke B; Li Z; Zhang W
EBioMedicine; 2016 Apr; 6():139-148. PubMed ID: 27211556
[TBL] [Abstract][Full Text] [Related]
7. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.
Ali A; Unnikannan H; Shafarin J; Bajbouj K; Taneera J; Muhammad JS; Hasan H; Salehi A; Awadallah S; Hamad M
Endocrine; 2022 Jun; 76(3):543-557. PubMed ID: 35237909
[TBL] [Abstract][Full Text] [Related]
8. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
10. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
[TBL] [Abstract][Full Text] [Related]
11. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
[TBL] [Abstract][Full Text] [Related]
12. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
13. Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
Leung AKK; Xue YC; de Guzman A; Grzelkovski G; Kong HJ; Genga KR; Russell JA; Boyd JH; Francis GA; Walley KR
Atherosclerosis; 2022 Dec; 362():29-37. PubMed ID: 36207148
[TBL] [Abstract][Full Text] [Related]
14. High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats.
Ou-Yang YN; Deng FF; Wang YJ; Chen M; Yang PF; Yang Z; Tian Z
Biochimie; 2024 Jan; 216():34-45. PubMed ID: 37844755
[TBL] [Abstract][Full Text] [Related]
15. Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling.
Qian Z; Zhao J
J Microbiol Biotechnol; 2022 Nov; 32(11):1406-1415. PubMed ID: 36330745
[TBL] [Abstract][Full Text] [Related]
16. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
17. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Dong B; Singh AB; Fung C; Kan K; Liu J
Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
19. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
20. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
